Aligos Therapeutics, Inc.
ALGSHealthcare|Biotechnology|US
$4.07
-0.44 (-9.76%)
DCF Value
$0.13
Tangible Book / Share
$1.08
Cash / Share
$2.97
Financials
Financial Snapshot
Market Cap
$25.4M
Enterprise Value
$6.2M
Revenue (TTM)
$30.8M
Net Income (TTM)
-$66.3M
Cash & Investments
$31.1M
Net Cash
$19.2M
Free Cash Flow (TTM)
-$68.7M
Operating CF (TTM)
-$68.4M
Debt/Equity
1.05
Cash Runway & Burn Rate
Cash on Hand
$31.1M
Quarterly Burn
$17.1M
Monthly Burn
$5.7M
Est. Runway
~1.8 quarters
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $90.9M | $117.7M | $243.5M | $190.7M | $125.8M | $135.7M | $56.9M | $77.8M | $31.1M | |
| Operating Cash Flow | -$6.0M | -$46.8M | -$74.3M | -$115.7M | -$79.4M | -$79.0M | -$80.7M | -$82.5M | -$68.4M | |
| Free Cash Flow | -$8.6M | -$49.6M | -$76.3M | -$116.6M | -$80.3M | -$79.0M | -$80.9M | -$82.9M | -$68.7M | |
| Capital Expenditure | -$2.5M | -$2.8M | -$2.1M | -$892.0K | -$943.0K | -$19.0K | -$130.0K | -$437.0K | -$289.0K | |
| Financing Cash Flow | $99.9M | $85.5M | $192.3M | $78.7M | $164.0K | $88.3M | $355.0K | $101.6M | $273.0K |
R&D Spending
R&D (TTM)
$83.3M
R&D Intensity
270.8%
R&D Growth vs Prior
+20.0%
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $4.4M | $13.9M | $15.5M | $3.9M | $2.2M | $30.8M | |
| R&D Expense | $10.5M | $44.0M | $79.9M | $104.2M | $85.1M | $73.0M | $70.3M | $69.5M | $83.3M | |
| R&D % of Revenue | — | — | — | 2389.4% | 611.8% | 470.3% | 1781.2% | 3177.2% | 270.8% | |
| SG&A | $3.2M | $10.0M | $14.6M | $28.5M | $26.4M | $30.6M | $22.8M | $20.7M | $22.6M |
Income Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $4.4M | $13.9M | $15.5M | $3.9M | $2.2M | $30.8M | |
| Cost of Revenue | $1.3M | $2.3M | $3.3M | $0.00 | $0.00 | $0.00 | $0.00 | $930.0K | $257.0K | |
| Gross Profit | -$1.3M | -$2.3M | -$3.3M | $4.4M | $13.9M | $15.5M | $3.9M | $1.3M | $30.5M | |
| R&D | $10.5M | $44.0M | $79.9M | $104.2M | $85.1M | $73.0M | $70.3M | $69.5M | $83.3M | |
| SG&A | $3.2M | $10.0M | $14.6M | $28.5M | $26.4M | $30.6M | $22.8M | $20.7M | $22.6M | |
| Operating Income | -$13.7M | -$54.0M | -$97.8M | -$128.3M | -$97.6M | -$88.1M | -$89.2M | -$88.0M | -$72.5M | |
| Interest Expense | $0.00 | $0.00 | $10.5M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$13.9M | -$52.2M | -$108.4M | -$128.2M | -$95.9M | -$86.9M | -$130.9M | -$23.9M | -$62.8M | |
| Net Income | -$13.9M | -$52.3M | -$108.5M | -$128.3M | -$96.0M | -$87.7M | -$131.2M | -$24.2M | -$66.3M | |
| EPS (Diluted) | -0.66 | -2.38 | -3.18 | -3.22 | -2.25 | -3.52 | -20.94 | -2.45 | -6.35 | |
| EBITDA | -$12.4M | -$49.9M | -$105.1M | -$124.4M | -$92.3M | -$83.8M | -$128.3M | -$22.9M | -$61.8M | |
| Shares Out. (M) | 21.17 | 21.93 | 34.18 | 39.86 | 42.70 | 24.87 | 6.26 | 9.88 | 10.46 |
Balance Sheet
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $24.0M | $69.6M | $220.4M | $186.8M | $81.3M | $135.7M | $37.0M | $18.3M | $31.1M | |
| Short-Term Investments | $66.8M | $48.1M | $23.1M | $3.9M | $44.5M | $0.00 | $19.9M | $59.5M | $0.00 | |
| Total Current Assets | $92.4M | $120.2M | $250.0M | $204.4M | $133.5M | $141.1M | $62.1M | $82.9M | $34.7M | |
| Total Assets | $107.7M | $146.5M | $265.3M | $235.4M | $146.7M | $151.5M | $70.1M | $88.5M | $47.2M | |
| Total Current Liabilities | $7.5M | $13.8M | $30.3M | $39.0M | $33.1M | $23.9M | $21.7M | $21.2M | $19.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $10.7M | |
| Total Liabilities | $121.5M | $211.4M | $45.3M | $50.6M | $42.8M | $59.4M | $99.1M | $35.0M | $35.9M | |
| Stockholders' Equity | -$13.7M | -$64.9M | $220.0M | $184.7M | $103.9M | $92.1M | -$29.0M | $53.5M | $11.3M | |
| Retained Earnings | -$13.9M | -$66.2M | -$174.7M | -$303.1M | -$399.1M | -$486.8M | -$618.0M | -$642.2M | -$688.6M |
Cash Flow Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.0M | -$46.8M | -$74.3M | -$115.7M | -$79.4M | -$79.0M | -$80.7M | -$82.5M | -$68.4M | |
| Capital Expenditure | -$2.5M | -$2.8M | -$2.1M | -$892.0K | -$943.0K | -$19.0K | -$130.0K | -$437.0K | -$289.0K | |
| Free Cash Flow | -$8.6M | -$49.6M | -$76.3M | -$116.6M | -$80.3M | -$79.0M | -$80.9M | -$82.9M | -$68.7M | |
| Investing Cash Flow | -$69.3M | $6.8M | $32.8M | $3.0M | -$26.3M | $45.0M | -$18.3M | -$37.8M | $57.8M | |
| Financing Cash Flow | $99.9M | $85.5M | $192.3M | $78.7M | $164.0K | $88.3M | $355.0K | $101.6M | $273.0K | |
| Issuance of Stock | $2.0K | $0.00 | $155.5M | $78.6M | $225.0K | $17.4M | $438.0K | $101.3M | -$101.2M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $5.0M | -$43.0K | -$58.0K | -$79.0K | -$61.0K | -$96.0K | -$83.0K | -$14.0K | -$143.0K | |
| Stock Based Comp. | $179.0K | $752.0K | $3.0M | $13.5M | $14.7M | $12.7M | $8.5M | $5.0M | $5.4M | |
| Net Change in Cash | $24.5M | $45.6M | $150.8M | -$34.0M | -$105.5M | $54.3M | -$98.7M | -$18.7M | -$10.3M |
Dilution Tracker
Shares Outstanding
6M
5-Year Share Growth
-71.1%
Stock Issuance (TTM)
-$101.2M
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 21.17 | 21.93 | 34.18 | 39.86 | 42.70 | 24.87 | 6.26 | 9.88 | 10.46 | |
| Change vs Prior % | — | 3.6% | 55.8% | 16.6% | 7.1% | -41.7% | -74.8% | 57.8% | 5.8% | |
| Stock Issuance | $2.0K | $0.00 | $155.5M | $78.6M | $225.0K | $17.4M | $438.0K | $101.3M | -$101.2M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $179.0K | $752.0K | $3.0M | $13.5M | $14.7M | $12.7M | $8.5M | $5.0M | $5.4M |
Margins & Profitability
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 57.5% | 99.2% | |
| Operating Margin % | — | — | — | -2943.8% | -701.7% | -567.5% | -2259.9% | -4024.9% | -235.6% | |
| Net Margin % | — | — | — | -2944.1% | -690.6% | -564.6% | -3326.0% | -1106.7% | -215.4% | |
| EBITDA Margin % | — | — | — | -2854.1% | -663.4% | -539.7% | -3251.2% | -1049.8% | -200.8% | |
| FCF Margin % | — | — | — | -2673.9% | -577.6% | -508.8% | -2050.0% | -3794.1% | -223.1% | |
| ROE % | 101.3% | 80.5% | -49.3% | -69.5% | -92.4% | -95.2% | 452.9% | -45.2% | -206.3% | |
| ROA % | -12.9% | -35.7% | -40.9% | -54.5% | -65.5% | -57.9% | -187.2% | -27.3% | -140.5% | |
| ROIC % | -13.5% | -40.0% | -41.2% | -64.4% | -83.6% | -67.3% | -172.1% | -123.9% | -251.6% | |
| R&D / Revenue % | — | — | — | 2389.4% | 611.8% | 470.3% | 1781.2% | 3177.2% | 270.8% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 219.0% | 11.7% | -74.6% | -44.6% | |
| Gross Profit | 0.0% | -78.1% | -44.6% | 231.1% | 219.0% | 11.7% | -74.6% | -68.2% | |
| Operating Income | 0.0% | -295.6% | -81.0% | -31.2% | 24.0% | 9.7% | -1.2% | 1.3% | |
| Net Income | 0.0% | -275.1% | -107.7% | -18.2% | 25.2% | 8.7% | -49.6% | 81.6% | |
| EPS (Diluted) | 0.0% | -260.6% | -33.6% | -1.3% | 30.1% | -56.4% | -494.9% | 88.3% | |
| Operating Cash Flow | 0.0% | -673.1% | -58.8% | -55.7% | 31.4% | 0.5% | -2.2% | -2.2% | |
| Free Cash Flow | 0.0% | -478.6% | -54.0% | -52.7% | 31.1% | 1.6% | -2.4% | -2.6% | |
| R&D Expense | 0.0% | 321.2% | 81.4% | 30.4% | -18.3% | -14.1% | -3.8% | -1.2% | |
| SG&A Expense | 0.0% | 212.2% | 46.1% | 95.1% | -7.4% | 15.9% | -25.4% | -9.3% | |
| Total Assets | 0.0% | 36.0% | 81.1% | -11.3% | -37.7% | 3.3% | -53.7% | 26.3% | |
| Book Value / Share | 0.0% | -355.6% | 317.6% | -28.0% | -47.5% | 52.1% | -224.9% | 217.1% | |
| Debt | 0.0% | 3.4% | -9.2% | 11.1% | -13.0% | -11.4% | -24.8% | -37.3% | |
| Diluted Shares | 0.0% | 3.6% | 55.8% | 16.6% | 7.1% | -41.7% | -74.8% | 57.8% |
Valuation
P/E (TTM)At Loss
P/S0.83
10Y Low / Med / High26.59 / 63.27 / 2713.26
P/B3.77
10Y Low / Med / High1.72 / 9.79 / 107.37
EV/EBITDAAt Loss
EV/Revenue0.20
10Y Low / Med / High18.57 / 56.01 / 2673.72
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.13
Tangible Book / Share
$1.08
Cash / Share
$2.97
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -562.50 | -155.99 | -217.37 | -92.16 | -10.59 | -4.72 | -1.90 | -3.80 | -0.64 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 2713.26 | 73.13 | 26.59 | 63.27 | 42.14 | 0.83 | |
| P/B Ratio | -571.70 | -125.47 | 107.37 | 64.02 | 9.79 | 4.48 | -8.61 | 1.72 | 3.77 | |
| EV/EBITDA | -634.57 | -162.12 | -222.91 | -93.68 | -10.28 | -3.44 | -1.72 | -3.45 | -0.10 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 2673.72 | 68.18 | 18.57 | 56.01 | 36.17 | 0.20 |
Analyst Estimates & Quality
Altman Z-Score
-23.39
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $36.0M | $4.1M | $65.1M |
| Net Income | -$65.7M | -$54.2M | -$6.1M |
| EPS | $-6.55 | $-5.37 | $-2.61 |
| # Analysts (EPS) | 4 | 6 | 6 |